Bavarian Nordic signs up U.S. firm for packaging monkeypox vaccine
Send a link to a friend
[August 19, 2022]
(Reuters) - Danish biotech firm
Bavarian Nordic said on Thursday it has signed up a U.S.-based
manufacturer to package its Jynneos monkeypox vaccine and the production
is expected to begin later this year.
The company aims to finish the technology transfer in three months to
Michigan-based Grand River Aseptic.
More than 13,500 cases of the disease, which cause flu-like symptoms and
skin lesions, have been reported in the United States as of Aug. 17.
The government's Biomedical Advanced Research and Development Authority,
which procures the vaccine, has requested 5.5 million doses for delivery
this year and the next, the company said.
This includes an additional order for 2.5 million doses that Bavarian
Nordic received last month.
Besides allowing faster deliveries to the United States, the agreement
will free up the company's capacity for other countries.
The Danish company has doubled its capacity from before the outbreak
started in May and expects to further increase it even as it explores
more partnerships to improve global access to the vaccine.
[to top of second column]
|
![](../images/081922PIX/health11.jpg)
An employee of the vaccine company Bavarian Nordic shows a picture
of a vaccine virus on a display in a laboratory of the company in
Martinsried near Munich, Germany, May 24, 2022. The company,
headquartered in Denmark, is the only one in the world to have
approval for a smallpox vaccine called Jynneos in the U.S. and
Imvanex in Europe, which is also effective against monkeypox.
REUTERS/Lukas Barth
![](http://archives.lincolndailynews.com/2017/Jul/22/images/ads/current/rohlfs_lda_072017.png) To boost the supply of monkeypox vaccines, the United States is
making an additional 1.8 million doses of the Jynneos vaccine
available for orders starting Aug. 22.
Cases of monkeypox have been rising globally, with over 38,800 cases
confirmed.
(Reporting by Amruta Khandekar and Leroy Leo; Editing by Shailesh
Kuber and Arun Koyyur)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |